Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) – Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 – 2020.
GosReports(http://www.gosreports.com/global-biosimilarsfollow-on-biologics-market-technology-types-applications-services-and-geography-size-share-global-trends-company-profiles-demand-insights-analysis-research-report-op/) has announced the addition of the " Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) – Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 – 2020.
Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020.
Regulations for biosimilars plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to...